The revenue beat and maintained guidance are positive, but the widening losses and dilutive $20M placement at $0.454/share create significant headwinds. With a pro-forma market cap of ~$44M and cash burn continuing, watch for Q3 tissue volume acceleration and path to positive adjusted EBITDA by year-end.
Price Chart
Executive Summary
mdxhealth reported Q2 2026 revenue of $27.2M (+16% YoY), beating consensus estimates, but net loss widened to $9.5M and adjusted EBITDA turned negative at -$2.3M vs +$1.1M a year ago, driven by ExoDx acquisition costs. The company completed the Resolve UTI wind-down and raised $20M via a registered direct placement at $0.454/share, adding pro-forma cash of $39.2M. While revenue growth and guidance of $110-115M for 2026 are positive, the expanding losses and dilutive offering temper the outlook, making this a mixed report for a micro-cap diagnostics company with a history of poor post-earnings stock performance.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $27.2M, up 16% YoY from $23.4M (consensus $22.5M)
- Net loss widened to $9.5M from $7.0M YoY, operating loss $5.1M vs $1.5M
- Adjusted EBITDA -$2.3M vs +$1.1M in prior year period
- Gross margin declined to 65.7% from 68.6% due to test mix shift
- Completed Resolve UTI wind-down; Delta Lab filed Assignment for Benefit of Creditors
- Raised $20M gross via registered direct placement of 44.05M shares at $0.454/share
- Pro-forma cash $39.2M after placement; 2026 revenue guidance $110-115M (20-26% growth)
- Tissue-based test volumes flat YoY but up 13% sequentially; liquid-based ExoDx volumes 13,578
Financial Impact
Revenue beat consensus by ~21% ($27.2M vs $22.5M), but operating loss more than doubled to $5.1M. Dilution from 44M-share placement at $0.454 adds ~85% to share count.
Risk Factors
- Dilution from 44M-share placement increases share count by ~85%, pressuring EPS
- Operating loss more than doubled to $5.1M; adjusted EBITDA turned negative
- Gross margin compression from test mix shift (65.7% vs 68.6%)
- Delta Lab ABC process exposes company to $10.4M Novitas recoupment claim
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344873 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 6-K | $0.2070 $0.1830 | ▲ +11.59% | ▲ +11.69% | $0.1932 (+6.67%) |
Oct 15, 2026 11d ago | SC 13D/A | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1932 (+6.49%) |
Oct 15, 2026 11d ago | Press Release | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1932 (+6.49%) |
Sep 17, 2026 5w ago | 144 | $0.6300 $0.5650 | ▲ +10.32% | ▲ +11.59% | $0.1932 (+69.33%) |
Sep 3, 2026 7w ago | 6-K | $0.7484 $0.7072 | ▲ +5.51% | ▲ +4.30% | $0.1932 (+74.18%) |
Aug 13, 2026 10w ago | 6-K | $0.8080 $0.7431 | ▲ +8.03% | ▲ +6.66% | $0.1932 (+76.09%) |
Aug 13, 2026 10w ago | Press Release | $0.8080 $0.7431 | ▼ −8.03% | ▼ −6.66% | $0.1932 (−76.09%) |
Jul 24, 2026 13w ago | 6-K | $0.4180 $0.4180 | · 0.00% | ▲ +1.07% | $0.1932 (+53.78%) |
Jul 2, 2026 16w ago | Press Release | $0.4765 $0.4899 | ▼ −2.81% | ▼ −1.88% | $0.1932 (+59.45%) |
Apr 29, 2026 25w ago | 6-K | $2.04 $2.01 | ▼ −1.47% | ▼ −3.20% | $0.1932 (−90.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers